Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹4,430 Cr revenue.
COGS 15.6%, employees 13.4%.
“We'll end the year with about $12.75 to 1,300 crores. More or less consistent with what we have given at the start of the year.”
“Contribution from Revlimid will drop dramatically for next two quarters. Guidance of 750-800 crores for quarter. Bad guidance of 135-150 crores per quarter.”
“Assets increased, went past 10,000 crores this quarter. Balance sheet strength has been dramatic.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 18.0%▲ | 10.5% |
| ROCE | 21.6%▲ | 13.8% |
| Net Margin | 32.1%▲ | 8.7% |
| EBITDA Margin | 44.2%▲ | 16.0% |
| Debt To Equity | 0.03x▼ | 0.21x |
| Rev Growth 3yr | 32.8%▲ | 5.8% |
| EPS Growth 3yr | 124.4%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹4,560 Cr +3.0% | ₹4,430 Cr +10.8% | ₹3,999 Cr +47.7% | ₹2,707 Cr +39.2% | ₹1,945 Cr -5.2% | ₹2,052 Cr +7.2% | ₹1,915 Cr -8.6% | ₹2,095 Cr |
| Other Income | ₹286 Cr -19.3% | ₹355 Cr +176.7% | ₹128 Cr +22.5% | ₹105 Cr +5.7% | ₹99 Cr -4.4% | ₹104 Cr -3.5% | ₹107 Cr -17.5% | ₹130 Cr |
| Total Income | ₹4,846 Cr +1.3% | ₹4,784 Cr +15.9% | ₹4,127 Cr +46.8% | ₹2,812 Cr +37.6% | ₹2,044 Cr -5.2% | ₹2,156 Cr +6.6% | ₹2,022 Cr -9.1% | ₹2,225 Cr |
| COGS | ₹785 Cr +13.8% | ₹690 Cr -3.7% | ₹717 Cr +14.2% | ₹627 Cr +11.8% | ₹561 Cr +9.7% | ₹511 Cr +34.0% | ₹382 Cr +7.7% | ₹354 Cr |
| ₹2,994 Cr +20.1% | ₹2,493 Cr +1.6% | ₹2,453 Cr +25.8% | ₹1,950 Cr +5.9% | ₹1,842 Cr +16.8% | ₹1,576 Cr +8.4% | ₹1,454 Cr +3.8% | ₹1,400 Cr | |
| Profit Before Tax | ₹1,853 Cr -19.1% | ₹2,291 Cr +36.9% | ₹1,674 Cr +94.2% | ₹862 Cr +326.3% | ₹202 Cr -65.1% | ₹580 Cr +1.9% | ₹569 Cr -31.0% | ₹825 Cr |
| ₹308 Cr -24.5% | ₹408 Cr +43.1% | ₹285 Cr +94.5% | ₹147 Cr +355.3% | ₹32 Cr -76.5% | ₹137 Cr +24.1% | ₹111 Cr -39.3% | ₹182 Cr | |
| Net Profit | ₹1,556 Cr -17.4% | ₹1,883 Cr +35.7% | ₹1,388 Cr +94.1% | ₹715 Cr +320.8% | ₹170 Cr -61.6% | ₹442 Cr -3.4% | ₹458 Cr -28.7% | ₹642 Cr |
| Profit (Owners) | ₹1,557 Cr -17.4% | ₹1,885 Cr +35.8% | ₹1,388 Cr +94.1% | ₹715 Cr +320.8% | ₹170 Cr -61.4% | ₹441 Cr -4.3% | ₹461 Cr -28.5% | ₹644 Cr |
| Minority Interest | (₹2 Cr) +15.0% | (₹2 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹2 Cr ↑ Recovery | (₹3 Cr) -35.0% | (₹2 Cr) |
| Other Comprehensive Income | ₹186 Cr ↑ Recovery | (₹24 Cr) ↓ Decline | ₹15 Cr +451.9% | ₹3 Cr -94.6% | ₹50 Cr +471.3% | ₹9 Cr ↑ Recovery | (₹15 Cr) -90.8% | (₹8 Cr) |
| EPS | ₹86.94 | ₹105.26 | ₹77.51 | ₹39.20 | ₹9.31 | ₹24.18 | ₹25.31 | ₹35.24 |
| Diluted Shares | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr | ₹18 Cr |
| Profit Or Loss Of Associates | ₹11 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Natco Pharma Limited has informed the Exchange about Transcript
Natco Pharma Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injecti...
Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Annual Audited Financial Results for the quarter and year ended March 31, 2026
Natco Pharma Limited has informed the Exchange about Link of Recording
Natco Pharma Limited has informed the Exchange about FY26 Earnings Presentation
Natco Pharma Limited has submitted to the Exchange, the Audited financial results for the quarter and year ended March 31, 2026.
Natco Pharma Limited has informed the Exchange about Schedule of meet
Natco Pharma Limited has informed the Exchange about Action(s) initiated or orders passed
Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Natco Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.
Natco Pharma Limited has informed the Exchange regarding a press release dated March 20, 2026, titled "NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Afforda...
Natco Pharma Limited has informed the Exchange about Schedule of meet
Natco Pharma Limited has informed the Exchange regarding a press release dated March 03, 2026, titled "NATCO announces launch of Pomalidomide Capsules (generic of Pomalyst®) in the U.S. market".
The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The respons...
The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The respons...